UP!
|
Type
|
Public |
|---|---|
| Traded as | NYSE: PMC S&P 600 Component |
| Industry |
|
| Headquarters | Louisville, Kentucky, U.S. |
|
Area served
|
United States |
| Website | www |
PharMerica is a publicly traded Fortune 1000 company formed in January 2007 from the merger of Kindred Healthcare's pharmacy business with a subsidiary of AmerisourceBergen. The company is headquartered in Louisville, Kentucky, and operates a major customer support center in Tampa, Florida.
The new company is the second largest in the institutional pharmacy services market, with revenues of $1.9 billion and a customer base of 330,000 "beds" in 41 U.S. states.
In August 2011, pharmacy services provider Omnicare made a bid of $457 million for all outstanding shares of PharMerica. The Federal Trade Commission sued Omnicare to block the deal on the basis that the FTC believed the acquisition would lead to higher drug prices. In February 2012, Omnicare allowed its offer to the shareholders of PharMerica to expire.
| 2016-06-07 | Initiated Coverage | Bank of America | Buy | $32.00 |
| 2016-06-07 | Initiated Coverage | Bank of America Corp. | Buy | $32.00 |
| 2016-05-10 | Reiterated Rating | Barrington Research | Outperform | $30.00 to $34.00 |
| 2016-03-15 | Initiated Coverage | Credit Suisse | Outperform | $30.00 |
| 2016-03-15 | Initiated Coverage | Credit Suisse Group AG | Outperform | $30.00 |
| 2016-02-29 | Reiterated Rating | Barrington Research | Outperform | $39.00 to $30.00 |
| 2016-02-29 | Lower Price Target | KeyBanc | Overweight | $39.00 to $32.00 |
| 2016-02-29 | Lower Price Target | Barclays | Underweight | $27.00 to $22.00 |
| 2016-02-29 | Lower Price Target | KeyCorp | Overweight | $39.00 to $32.00 |
| 2016-02-29 | Lower Price Target | Barclays PLC | Underweight | $27.00 to $22.00 |
| 2015-12-30 | Reiterated Rating | Cowen and Company | Buy | $39.00 to $41.00 |
| 2015-12-30 | Reiterated Rating | Credit Suisse | Outperform | $39.00 |
| 2015-11-09 | Boost Price Target | Barclays | Underweight | $22.00 to $27.00 |
| 2015-11-06 | Reiterated Rating | Cowen and Company | Buy | $39.00 |
| 2015-08-10 | Boost Price Target | Barrington Research | Outperform | $33.00 to $38.00 |
| 2015-07-14 | Reiterated Rating | Bank of America | Buy | $34.00 to $39.00 |
| 2014-11-20 | Initiated Coverage | Barrington Research | Outperform | $30.00 |
| 2014-11-07 | Reiterated Rating | Barclays | Underweight | $26.00 to $25.00 |
| 2014-09-11 | Initiated Coverage | Goldman Sachs | Neutral | $29.00 |
| 2014-09-11 | Initiated Coverage | Goldman Sachs Group Inc. | Neutral | $29.00 |
| 2014-09-03 | Upgrade | Cowen and Company | Market Perform to Outperform | $31.00 to $33.00 |
| 2014-07-17 | Initiated Coverage | Barclays | Underweight | |
| 2014-07-02 | Reiterated Rating | Evercore ISI | Positive | |
| 2014-06-09 | Reiterated Rating | KeyBanc | Buy | $31.00 to $33.00 |
| 2014-05-02 | Reiterated Rating | Barclays | Underweight | $26.00 |
| 2014-03-12 | Upgrade | Credit Suisse | Neutral to Outperform | $19.00 to $30.00 |
| 2014-03-04 | Boost Price Target | RBC Capital | $18.00 to $21.00 | |
| 2014-01-08 | Boost Price Target | Barclays | Underweight | $14.00 to $16.00 |
| 2013-11-07 | Boost Price Target | Barclays | Underweight | $12.00 to $14.00 |
| 2013-11-06 | Boost Price Target | Cowen and Company | Market Perform | $16.00 to $20.00 |
| 2013-11-05 | Boost Price Target | KeyBanc | Buy | $17.00 to $21.00 |
| 2013-10-03 | Initiated Coverage | KeyBanc | Buy | $17.00 |
| 2011-10-03 | Reiterated | UBS | Neutral | $13 to $15 |
| 2010-11-08 | Reiterated | Oppenheimer | Perform | $10 to $12 |
| 2010-08-18 | Downgrade | Barclays Capital | Overweight to Equal Weight | $19 to $10 |
| 2010-04-23 | Upgrade | Thomas Weisel | Market Weight to Overweight | $25 |
| 2010-02-08 | Reiterated | Barclays Capital | Overweight | $18 to $19 |
| 2009-08-04 | Downgrade | Oppenheimer | Outperform to Perform | $26 to $23 |
| 2009-01-22 | Initiated | Credit Suisse | Neutral | $18 |
| 2008-12-08 | Reiterated | Stifel Nicolaus | Buy | $10 to $7 |
| 2008-12-03 | Reiterated | Leerink Swann | Mkt Perform | $20 to $16.50 |
| 2016-06-07 | Initiated Coverage | Bank of America | Buy | $32.00 |
| 2016-06-07 | Initiated Coverage | Bank of America Corp. | Buy | $32.00 |
| 2016-05-10 | Reiterated Rating | Barrington Research | Outperform | $30.00 to $34.00 |
| 2016-03-15 | Initiated Coverage | Credit Suisse | Outperform | $30.00 |
| 2016-03-15 | Initiated Coverage | Credit Suisse Group AG | Outperform | $30.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In PMC 14 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Fund Advisors | 2.67M |
| BlackRock Institutional Trust Company, N.A. | 0.78M |
| MANAGED ACCOUNT ADVISORS LLC | 0.36M |
| BlackRock Investment Management, LLC | 0.17M |
| Shinko Asset Management Co., Ltd. | 89621 |
| LOMBARDIA CAPITAL PARTNERS LLC | 72134 |
| BlackRock Group LTD | 62301 |
| Century Capital Management, LLC | 38638 |
| VTL Associates, LLC | 33192 |
| BLACKROCK ADVISORS LLC | 16723 |
| CAPSTONE ASSET MANAGEMENT CO | 16041 |
| Independence Capital Asset Partners, LLC | 10294 |
| RUSSELL FRANK CO/ | 887 |
| WFG Advisors, LP | 35 |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| CULOTTA MICHAEL J EVP and CFO | 0.61% (183369) | PMC / QHC / |
| FROESEL DAVID W JR Executive VP, CFO & Treasurer | 0.27% (82371) | PMC / |
| MAC MAHON THOMAS P | 0.19% (58606) | ESRX / PMC / |
| GERRITY THOMAS P | 0.18% (53312) | ACTA / PMC / |
| Hernandez Anthony SVP of Human Resources | 0.15% (44969) | PMC / |
| Lindemoen Mark SVP Sales and Client Services | 0.08% (25036) | PMC / |
UM